3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
relugolix
1
palbociclib
1
nilotinib
1
isatuximab
1
inavolisib
1
giredestrant
1
enzalutamide
1
avelumab
1
atezolizumab
1
acalabrutinib
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Tyrosine Kinase Inhibitors
×
90 days
×
Clear all
No trials found.